Patents Assigned to Medical Research Council
-
Publication number: 20200297668Abstract: The present invention relates to inhibitors of PPP1 R15A and PPP1 R15B and their use in therapy, particularly in the treatment of a disease state alleviated by the inhibition of PPP1 R15A and PPP1 R15B, for example a disorder associated with accumulation of misfolded proteins or proteostatsis disorder. Compounds of the invention include compounds having the formula IA or a pharmaceutically acceptable salt thereof, wherein R1a, R3a, R5a, Xa and Ya are as defined herein.Type: ApplicationFiled: February 28, 2020Publication date: September 24, 2020Applicant: Medical Research CouncilInventors: Anne BERTOLOTTI, Indrajit DAS, Agnieszka KRZYZOSIAK, Adrien ROUSSEAU, Kim SCHNEIDER, Anna Gudny SIGURDARDOTTIR
-
Publication number: 20200197337Abstract: The present invention relates to inhibitors of PPP1 R15A and PPP1 R15B and their use in therapy, particularly in the treatment of a disease state alleviated by the inhibition of PPP1 R15A and PPP1 R15B, for example a disorder associated with accumulation of misfolded proteins or proteostatsis disorder. Compounds of the invention include compounds having the formula IA or a pharmaceutically acceptable salt thereof, wherein R1a, R3a, R5a, Xa and Ya are as defined herein.Type: ApplicationFiled: February 28, 2020Publication date: June 25, 2020Applicant: Medical Research CouncilInventors: Anne BERTOLOTTI, Indrajit DAS, Agnieszka KRZYZOSIAK, Adrien ROUSSEAU, Kim SCHNEIDER, Anna Gudny SIGURDARDOTTIR
-
Publication number: 20200190161Abstract: The present invention relates to mutant transmembrane proteins which have increased conformational stability when compared to their parent protein, methods of selection and production. In particular the invention relates to mutant transmembrane proteins which are mutated in or in the proximity of the transmembrane alpha helices or in a kinked region or in an alpha-helix adjacent to a kink. The mutant transmembrane proteins have use in crystallisation studies and also in screening to identify compounds for use in drug discovery and therapy.Type: ApplicationFiled: November 25, 2019Publication date: June 18, 2020Applicant: Medical Research CouncilInventor: Christopher Gordon Tate
-
Publication number: 20200155453Abstract: Processes for recovering colloids of carboxylate ligand modified ferric iron hydroxide materials such as IHAT (Iron Hydroxide Adipate Tartrate) are described based on the use of water miscible non-aqueous solvents, such as ethanol, methanol and acetone. The processes produce materials with advantageous properties such as improved bioavailability, reduced aggregation and/or agglomeration and/or increased iron content.Type: ApplicationFiled: January 21, 2020Publication date: May 21, 2020Applicant: Medical Research CouncilInventors: Jonathan Joseph Powell, Nuno Jorge Rodrigues Faria
-
Patent number: 10596122Abstract: Amorphous magnesium-substituted calcium, phosphate compositions and their medical uses are described, in particular for use in delivering cargo materials, such as cargo molecules or cargo nanoparticles contained in pores of the amorphous magnesium-substituted calcium phosphate to cells of the immune system, for example as therapeutic approaches for the treatment of inflammatory bowel diseases, and in particular Crohn's disease, autoimmune diseases, allergy and for therapeutic vaccination.Type: GrantFiled: November 5, 2014Date of Patent: March 24, 2020Assignee: Medical Research CouncilInventors: Jonathan Joseph Powell, Nuno Jorge Rodriguez Faria, Laetitia Pele, Rachel Hewitt, Emma Thomas-McKay
-
Patent number: 10544202Abstract: The present invention relates to mutant transmembrane proteins which have increased conformational stability when compared to their parent protein, methods of selection and production. In particular the invention relates to mutant transmembrane proteins which are mutated in or in the proximity of the transmembrane alpha helices or in a kinked region or in an alpha-helix adjacent to a kink. The mutant transmembrane proteins have use in crystallisation studies and also in screening to identify compounds for use in drug discovery and therapy.Type: GrantFiled: February 12, 2018Date of Patent: January 28, 2020Assignee: Medical Research CouncilInventor: Christopher Gordon Tate
-
Publication number: 20190062812Abstract: The invention relates to a method for the diagnosis of TB in a subject, the method comprising (a) providing a sample from said subject, said sample being selected from the group consisting of: blood, serum and plasma; (b) determining the concentration in said sample of the following biomarkers: IL-1ra, IL6, IL-7, IL-8, IL-12p70, FGF-basic, IP-10, and VEGF; (c) converting each biomarker concentration determined in (b) into a decile value; and (d) converting each decile value into a binary presence or absence by comparing the decile values of (c) to the following specific quantile cut off values wherein a decile value matching or exceeding the specific quantile cut-off value is converted into the binary presence of the biomarker, and a decile value lower than the specific quantile cut-off value is converted into the binary absence of the biomarker; wherein detecting the presence of each of said biomarkers indicates that the subject has TB. The invention also relates to uses, kits and devices.Type: ApplicationFiled: February 3, 2017Publication date: February 28, 2019Applicants: Medical Research Council, Imperial Innovations LimitedInventors: Beate KAMPMANN, Toyin TOGUN, Clive HOGGART
-
Publication number: 20190024261Abstract: The invention describes a method for the synthesis of compounds comprising the steps of: (a) compartmentalizing two or more sets of primary compounds into microcapsules; such that a proportion of the microcapsules contains two or more compounds; and (b) forming secondary compounds in the microcapsules by chemical reaction between primary compounds from different sets; wherein one or both of steps (a) and (b) is performed under microfluidic control; preferably electronic microfluidic control. The invention further allows for the identification of compounds which bind to a target component of a biochemical system or modulate the activity of the target, and which is co-compartmentalized into the microcapsules.Type: ApplicationFiled: December 8, 2017Publication date: January 24, 2019Applicants: President and Fellows of Harvard College, Medical Research CouncilInventors: Andrew David Griffiths, David A. Weitz, Darren Roy Link, Keunho Ahn, Jerome Bibette
-
Publication number: 20180282395Abstract: The present invention relates to mutant transmembrane proteins which have increased conformational stability when compared to their parent protein, methods of selection and production. In particular the invention relates to mutant transmembrane proteins which are mutated in or in the proximity of the transmembrane alpha helices or in a kinked region or in an alpha-helix adjacent to a kink. The mutant transmembrane proteins have use in crystallisation studies and also in screening to identify compounds for use in drug discovery and therapy.Type: ApplicationFiled: February 12, 2018Publication date: October 4, 2018Applicant: Medical Research CouncilInventor: Christopher Gordon Tate
-
Publication number: 20180271784Abstract: Processes for recovering colloids of carboxylate ligand modified ferric iron hydroxide materials such as IHAT (Iron Hydroxide Adipate Tartrate) are described based on the use of water miscible non-aqueous solvents, such as ethanol, methanol and acetone. The processes produce materials with advantageous properties such as improved bioavailability, reduced aggregation and/or agglomeration and/or increased iron content.Type: ApplicationFiled: October 7, 2016Publication date: September 27, 2018Applicant: Medical Research CouncilInventors: Jonathan Joseph POWELL, Nuno Jorge Rodrigues FARIA
-
Publication number: 20180272299Abstract: The invention describes a method for the synthesis of compounds comprising the steps of: (a) compartmentalising two or more sets of primary compounds into microcapsules; such that a proportion of the microcapsules contains two or more compounds; and (b) forming secondary compounds in the microcapsules by chemical reactions between primary compounds from different sets; wherein one or both of steps (a) and (b) is performed under microfluidic control; preferably electronic microfluidic control The invention further allows for the identification of compounds which bind to a target component of a biochemical system or modulate the activity of the target, and which is co-compartmentalised into the microcapsules.Type: ApplicationFiled: March 15, 2018Publication date: September 27, 2018Applicants: President and Fellows of Harvard College, Medical Research CouncilInventors: Andrew David Griffiths, David A. Weitz, Darren Roy Link, Keunho Ahn, Jerome Bibette
-
Publication number: 20180237756Abstract: The invention relates to a nucleic acid polymerase capable of producing a non-DNA nucleotide polymer from a DNA nucleotide template, said polymerase comprising amino acid sequence having at least 36% identity to the amino acid sequence of SEQ ID NO:1, wherein said amino acid sequence is mutated relative to the amino acid sequence of SEQ ID NO:1 at one or more residues of the thumb region, said residues selected from: amino acids 651 to 679 (patch 10A); wherein said amino acid sequence is mutated relative to the amino acid sequence of SEQ ID NO:1 at residue E664. In one embodiment said polymerase comprises the mutations Y409G and E664K. In one embodiment said polymerase comprises amino acid sequence corresponding to SEQ ID NO:12.Type: ApplicationFiled: March 13, 2018Publication date: August 23, 2018Applicant: MEDICAL RESEARCH COUNCILInventors: Philipp Holliger, Christopher Cozens, Vitor B. Pinheiro, Alexander I. Taylor
-
Patent number: 10052605Abstract: Methods for use in the synthesis and identification of molecules which bind to a target component of a biological system or modulate the activity of a target are described.Type: GrantFiled: April 29, 2010Date of Patent: August 21, 2018Assignee: Medical Research CouncilInventors: Andrew David Griffiths, Chris Abell, Florian Hollfelder, Enrico Mastrobattista
-
Publication number: 20180147177Abstract: Antibacterial compositions comprising nanoparticles formed from copper oxo-hydroxide are described that are capable of delivering biocidal concentrations of copper, typically in the form of free copper ions (Cu2+). The nanoparticle compositions generally comprise small particles, typically having mean diameters in the range of 1-100 nm, having comparatively high surface area-to-volume ratio and enhanced reactivity compared to the corresponding bulk counterpart materials and which are sufficiently labile to release the free copper efficiently.Type: ApplicationFiled: April 22, 2016Publication date: May 31, 2018Applicant: Medical Research CouncilInventors: Carlos André Passos BASTOS, Sylvaine Francoise Aline BRUGGRABER, Nuno Jorge Rodrigues FARIA, Jonathan Joseph POWELL
-
Patent number: 9968690Abstract: The invention relates to a polypeptide comprising an amino acid having a norbornene group. Suitably said norbornene group is present as an amino acid residue of a norbornene lysine. The invention also relates to a method of producing a polypeptide comprising a norbornene group, said method comprising genetically incorporating an amino acid comprising a norbornene group into a polypeptide.Type: GrantFiled: January 21, 2013Date of Patent: May 15, 2018Assignees: Medical Research Council, North Carolina State UniversityInventors: Jason Chin, Alexander Deiters, Kathrin Lang
-
Publication number: 20180125801Abstract: The present invention discloses a method to discover selective inhibitors of phosphatases.Type: ApplicationFiled: April 8, 2016Publication date: May 10, 2018Applicant: MEDICAL RESEARCH COUNCILInventors: Anne BERTOLOTTI, Indrajit DAS, Agnieszka KRZYZOSIAK, Adrien ROUSSEAU, Kim SCHNEIDER, Anna Gudny SIGURDARDOTTIR
-
Patent number: 9963474Abstract: The invention relates to compounds having Formula (1): A-L-B or pharmaceutically acceptable salts thereof, wherein: A is a dicarbonyl sequestering moiety comprising a substituted aryl group or a substituted heteroaryl group; L is an optional linker moiety; and B is a mitochondrial targeting moiety. The invention also relates to pharmaceutical compositions containing such compounds and salts, and to the use of such compounds and salts for treating diabetes, preferably hyperglycemic diabetes. A mass spectrometry probe and to a method of labelling a biological molecule 1 for mass spectrometry detection are also described.Type: GrantFiled: November 21, 2014Date of Patent: May 8, 2018Assignee: Medical Research CouncilInventors: Michael Patrick Murphy, Robin Andrew James Smith, Richard Charles Hartley
-
Publication number: 20180111896Abstract: The present invention relates to inhibitors of PPP1 R15A and PPP1 R15B and their use in therapy, particularly in the treatment of a disease state alleviated by the inhibition of PPP1 R15A and PPP1 R15B, for example a disorder associated with accumulation of misfolded proteins or proteostatsis disorder. Compounds of the invention include compounds having the formula IA or a pharmaceutically acceptable salt thereof, wherein R1a, R3a, R5a, Xa and Ya are as defined herein.Type: ApplicationFiled: April 8, 2016Publication date: April 26, 2018Applicant: MEDICAL RESEARCH COUNCILInventors: Anne BERTOLOTTI, Indrajit DAS, Agnieszka KRZYZOSIAK, Adrien ROUSSEAU, Kim SCHNEDIDER, Anna Gudny SICURDARDOTTIR
-
Patent number: 9947505Abstract: Some embodiments are directed to a support for receiving a biological sample, the support comprising at least one support member, and including graphene attached to the support member. The graphene is partially hydrogenated graphene. Some embodiments are also directed to use of a partially hydrogenated graphene surface to support a biological molecule for electron microscopy. Some other embodiments are also directed to a method for making a partially hydrogenated graphene. The method includes applying a hydrogen ion or hydrogen atom to the surface of graphene. The hydrogen ion or hydrogen atom is applied at an energy in the range 1 to 21 eV. A sensor comprising a surface capable of adsorbing a biological molecule thereto is also disclosed, wherein said surface includes partially hydrogenated graphene.Type: GrantFiled: August 7, 2014Date of Patent: April 17, 2018Assignee: MEDICAL RESEARCH COUNCILInventors: Christopher J. Russo, Lori A. Passmore
-
Patent number: 9938511Abstract: The invention relates to a nucleic acid polymerase capable of producing a non-DNA nucleotide polymer from a DNA nucleotide template, said polymerase comprising amino acid sequence having at least 36% identity to the amino acid sequence of SEQ ID NO:1, wherein said amino acid sequence is mutated relative to the amino acid sequence of SEQ ID NO:1 at one or more residues of the thumb region, said residues selected from: amino acids 651 to 679 (patch 10A); wherein said amino acid sequence is mutated relative to the amino acid sequence of SEQ ID NO:1 at residue E664. In one embodiment said polymerase comprises the mutations Y409G and E664K. In one embodiment said polymerase comprises amino acid sequence corresponding to SEQ ID NO:12.Type: GrantFiled: October 1, 2015Date of Patent: April 10, 2018Assignee: Medical Research CouncilInventors: Philipp Holliger, Christopher Cozens, Vitor B. Pinheiro, Alexander I. Taylor